logo
  Join        Login             Stock Quote

Tranzyme (TZYM) Drops After Disappointing ULISES 007 Trial Results

 March 12, 2012 08:30 AM


Tranzyme Inc. (NASDAQ:TZYM), a clinical-stage bio-pharmaceutical company, said the preliminary analysis of its ULISES 007 pivotal trial evaluating ulimorelin indicated study failed to meet its primary and secondary efficacy endpoints, sending its shares 70.59% lower in premarket trading.

Tranzyme and Norgine B.V. announced top-line results of the primary analysis of ULISES 007, the first of two Phase 3 pivotal trials evaluating ulimorelin, which failed to meet its primary and secondary efficacy endpoints.

While still planning to analyze the data from the second phase 3 trial ULISES 008, which the company expects by the end of the second quarter, Tranzyme is stopping all other NDA activities for ulimorelin.

[Related -Stocks Extend Decline Amid Weak Data; Netapp (NTAP) Surges]

The results of ULISES 007 show that ulimorelin, at both 160 and 480 micrograms/kg doses, was not statistically different from placebo for the primary endpoint, the time to recovery of GI function as defined by the time from the end of surgery to GI2. GI2 is defined as the later of first bowel movement and tolerance of solid food.

Key summary data include: median time to GI2 was approximately 80 hours in all arms; median duration of therapy was about 3.5 days in all arms; and both doses of ulimorelin were well tolerated.

ULISES (ULImorelin Safety and Efficacy Study) 007 is one of two Phase 3 pivotal, double-blind, multinational, placebo-controlled studies to evaluate the efficacy and safety of IV ulimorelin administered postoperatively to accelerate GI recovery in subjects who have undergone partial bowel resection.

[Related -U.S. Stocks End Mixed On China Trade Data; Hot Stocks: ORCL, ZOLL, HOG, PCBC, GMCR]

The study was designed to randomize about 330 patients to once-daily IV administration of 160 micrograms/kg of ulimorelin, 480 micrograms/kg of ulimorelin, or placebo. Top-line results in the second pivotal trial, ULISES 008 (identical in design and population to ULISES 007), are expected to be announced by the end of the second quarter 2012.

Tranzyme Chief Executive Vipin Garg said the company is now focusing on oral drug TZP-102 which is currently in a phase 2b trial for the treatment of diabetic gastroparesis. In this trial, the company is looking for improvement in upper GI symptoms over a twelve-week treatment period.

TZYM closed Friday's regular trading down 0.59% at $5.10. The stock has been trading between $2.38 and $5.70 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageUpbeat Forecasts For US Housing Sales In March

The Fiscal Times advises that the “the housing market is about to perk up.” One of the reasons for the read on...

article imageHappy Birthday, Moore's Law - Pearls of Wisdom for Investors

As Moore’s Law turns 50, we reflect on technology’s incredible history and limitless read on...

article imageIndex Investing Is Not Inherently Socialistic

How does capital get allocated to the public stock read on...

article imageDon't Let Fear of a 'Grexit' Keep You Out of European Stocks

After nearly three years of extremely weak economic growth, the European Central Bank is finally delivering read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.